Pediatric Vaccine Market to exceed US$ 48 Billion by 2024
- 6 years ago
Access full Research:
https://www.renub.com/pediatric-vaccines-market-doses-immunization-cases-and-forecast-worldwide-analysis-166-p.php
As per Renub Research analysis Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.
Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.
Request a free sample copy of the report:
https://www.renub.com/contactus.php
Renub Research report titled “Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.
By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years
The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.
https://www.renub.com/pediatric-vaccines-market-doses-immunization-cases-and-forecast-worldwide-analysis-166-p.php
As per Renub Research analysis Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.
Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.
Request a free sample copy of the report:
https://www.renub.com/contactus.php
Renub Research report titled “Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.
By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years
The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.